



Price Sensitive Information

This is for information of all concerned that the Board of Directors of Techno Drugs Limited in its 190th Board Meeting held on 31st January, 2026 at 4.00 P.M has approved the un-audited half yearly Financial Statements of the company for the period ended 31st December, 2025. Some key financial indicators of the company are given below:

Particulars	Amount (Taka)			
	31 st December, 2025		30 th June, 2025	
Net Asset Value (NAV) per Share with Revaluation	31.08		30.58	
Net Asset Value (NAV) per Share without Revaluation	27.38		26.88	
	July-Dec. 2025	July-Dec. 2024	Oct.-Dec. 2025	Oct.-Dec. 2024
Basic Earnings per Share (EPS)	0.87	1.08	0.40	0.48
Net Operating Cash Flow per Share (NOCFPS)	1.11	0.19	-	-

Reasons for Significant Variance:

The company's Earnings Per Share (EPS), Cash Flow from operation and NAV are 0.87, 1.11 and 31.08 respectively July to December 2025 against 1.08, 0.19 and 30.58 in the previous period July to December 2024. So, there is significant deviation. The company's Earnings Per Share (EPS) has decreased due to lower sales revenue and increased financial expenses compare to the previous period. Net Cash Flow from operation (NOCFPS) increase due to decrease of paid to supplier and others.

The details of un-audited half yearly Financial Statements for the period ended 31st December, 2025 is also available in the company's website www.technodrugsLtd.com.

Date: Dhaka
31st January, 2026.

By order of the Board of Directors

Sd/-
Debasish Das Gupta
Company Secretary